- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004811
Phase I/II Study of Itraconazole for Blastomycosis, Histoplasmosis, and Sporotrichosis
OBJECTIVES: I. Evaluate the tolerance of patients with blastomycosis, histoplasmosis, and sporotrichosis to different doses of itraconazole (R51,211).
II. Determine levels of itraconazole in serum and other body fluids. III. Assess the course of illness during itraconazole therapy. IV. Determine the dosage of itraconazole that is safe and well tolerated by 80%-90% of patients and estimate the potential of this dosage for use in future comparative trials.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PROTOCOL OUTLINE: This is a study to estimate the optimal dose of oral itraconazole. Patients are treated at 1 of 3 doses of itraconazole; the starting dose for each patient is determined at entry.
Therapy is administered daily for 3-6 months. Patients with progressive disease may be treated at the next higher dose; there may be only 1 such increase. Concurrent systemic and topical antifungals are prohibited.
Patients are followed at 1, 3, 6, and 12 months.
Study Type
Enrollment
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics-- Culture-proven fungal disease, i.e.: Chronic cavitary histoplasmosis Extrapulmonary histoplasmosis, e.g., mucosal disease Blastomycosis Sporotrichosis Positive culture after last dose of any prior therapy Requires antifungal therapy with amphotericin B or ketoconazole No fungal meningitis No central nervous system disease No immediately life-threatening disease --Prior/Concurrent Therapy-- At least 1 month since therapy for same disease No more than 2 mg/kg prior amphotericin B (total dose) No more than 2 mg/kg prior ketoconazole (total dose) No concurrent immunosuppressives, including: Corticosteroids Azathioprine Cytotoxic agents --Patient Characteristics-- Hepatic: AST no greater than 3 times normal Alkaline phosphatase no greater than 3 times normal Bilirubin no greater than 3 mg/dL Other: No acquired immunodeficiency syndrome No pregnant or nursing women Effective contraception required of fertile women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections and Mycoses
- Skin Diseases, Infectious
- Mycoses
- Dermatomycoses
- Lung Diseases, Fungal
- Histoplasmosis
- Blastomycosis
- Sporotrichosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Antifungal Agents
- Steroid Synthesis Inhibitors
- 14-alpha Demethylase Inhibitors
- Itraconazole
Other Study ID Numbers
- 199/12013
- NIAID-MSG-6A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Histoplasmosis
-
Barnes Retina InstituteGenentech, Inc.UnknownPresumed Ocular Histoplasmosis (POHS)United States
-
John Kitchens, MDUnknown
-
Barnes Retina InstitutePfizerTerminated
-
Retina Research Institute, LLCCompletedChoroidal Neovascularization | Presumed Ocular HistoplasmosisUnited States
-
Retina Associates of KentuckyGenentech, Inc.UnknownOcular Histoplasmosis SyndromeUnited States
-
Alessandro PasqualottoHospital de Clinicas de Porto Alegre; Irmandade Santa Casa de Misericórdia... and other collaboratorsCompletedAIDS | HistoplasmosisBrazil
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | HistoplasmosisUnited States
-
ANRS, Emerging Infectious DiseasesUnknown
-
National Eye Institute (NEI)CompletedMacular Degeneration | Histoplasmosis
-
Janssen, LPCompletedHIV Infections | HistoplasmosisUnited States
Clinical Trials on itraconazole
-
University of Maryland, BaltimoreCompleted
-
University of Alabama at BirminghamWashington University School of Medicine; University of California, DavisCompletedInvasive Fungal InfectionsUnited States, Panama
-
Johns Hopkins UniversityMemorial Sloan Kettering Cancer CenterCompleted
-
University of Kansas Medical CenterUniversity of Texas, Southwestern Medical Center at DallasRecruitingBarrett Oesophagitis With DysplasiaUnited States
-
Halcygen Pharmaceuticals LimitedCompletedOnychomycosisUnited States
-
H. Lundbeck A/SCompletedCytochrome P450 InteractionUnited Kingdom, United States
-
Sara BotrosCompleted
-
Pulmatrix Inc.Completed
-
Stiefel, a GSK CompanyGlaxoSmithKlineCompletedOnychomycosisUnited States, South Africa, Canada, Dominican Republic, Ecuador, Honduras, Panama
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedNon-small Cell Lung Cancer MetastaticUnited States